Floatz logo

Atezolizumab

Locally Advanced Ureter Urothelial Carcinoma

Alliance for Clinical Trials in Oncologymonoclonal_antibodyPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Locally Advanced Ureter Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3B

View all 20 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →